Solstein Capital LLC Takes Position in TELA Bio, Inc. $TELA

Solstein Capital LLC purchased a new stake in TELA Bio, Inc. (NASDAQ:TELA) in the second quarter, Holdings Channel reports. The firm purchased 16,385 shares of the company’s stock, valued at approximately $32,000.

Other institutional investors have also made changes to their positions in the company. Destiny Wealth Partners LLC bought a new stake in shares of TELA Bio in the 2nd quarter valued at approximately $102,000. Birchview Capital LP increased its holdings in shares of TELA Bio by 24.0% in the 1st quarter. Birchview Capital LP now owns 155,000 shares of the company’s stock valued at $189,000 after acquiring an additional 30,000 shares during the last quarter. Paradigm Capital Management Inc. NY bought a new stake in shares of TELA Bio in the 1st quarter valued at approximately $244,000. Finally, Velan Capital Investment Management LP acquired a new position in TELA Bio during the 1st quarter valued at approximately $912,000. 94.35% of the stock is currently owned by institutional investors.

TELA Bio Stock Performance

Shares of TELA stock opened at $1.48 on Tuesday. The company has a debt-to-equity ratio of 4.14, a quick ratio of 2.59 and a current ratio of 3.19. TELA Bio, Inc. has a 1 year low of $0.86 and a 1 year high of $3.26. The stock has a fifty day moving average of $1.59 and a two-hundred day moving average of $1.56. The firm has a market capitalization of $58.64 million, a PE ratio of -1.32 and a beta of 0.91.

TELA Bio (NASDAQ:TELA) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.04). TELA Bio had a negative return on equity of 329.48% and a negative net margin of 54.12%.The business had revenue of $20.20 million for the quarter, compared to analyst estimates of $20.67 million. TELA Bio has set its FY 2025 guidance at EPS. As a group, research analysts expect that TELA Bio, Inc. will post -1.37 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of TELA Bio in a research report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, TELA Bio presently has a consensus rating of “Hold” and a consensus price target of $4.50.

About TELA Bio

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.